CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 80.21×, higher than 95% of its Biotechnology peers (median 5.64×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
550.13MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
753.39%vs all stocks
Market Capitalization
550.13MUSDvs all stocks (USD)
Enterprise Value
-56.63MUSDvs all stocks (USD)
Forward P/E
-12.78xvs Biotechnology peers
Price to Book (MRQ)
0.5162xvs Biotechnology peers
Enterprise to EBITDA
4.09xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-14.38%vs Biotechnology peers
Return on Equity (TTM)
-25.62%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-13.86MUSDvs all stocks (USD)
Net Income (TTM)
-15.01MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-12.09MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-7.74MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-59.10MUSDvs all stocks (USD)
Pre-tax Income
-57.39MUSDFY2025 · Dec 31, 2025Net Income
-57.39MUSDFY2025 · Dec 31, 2025EBIT
-59.10MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-59.42MUSDFY2025 · Dec 31, 2025Research & Development
26.88MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
32.22MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.40MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.45USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.45USDFY2025 · Dec 31, 2025Basic Shares Outstanding
39.48MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
39.48MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-57.39MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-44.08MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
3.50MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-57.39MUSDFY2025 · Dec 31, 2025Stock-based Compensation
14.96MUSDFY2025 · Dec 31, 2025Other Non-cash Items
905.23KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-2.56MUSDFY2025 · Dec 31, 2025Purchase of Investments
-83.83MUSDFY2025 · Dec 31, 2025Sale of Investments
35.69MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-48.14MUSDFY2025 · Dec 31, 2025Other Financing Charges
-73.02KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
93.56MUSDFY2025 · Dec 31, 2025Shares Outstanding
104.89MSharesUpdated Jul 19, 2026Float Shares
7.72MSharesUpdated Jul 19, 2026Shares Short
10.65MSharesUpdated Jul 19, 2026Short Ratio
4.44daysvs all stocks
Short % of Shares Outstanding
10.78%vs all stocks
% Held by Insiders
2.90%vs all stocks
% Held by Institutions
89.66%vs all stocks
Total Cash (MRQ)
116.44MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
10.22USDUpdated Jul 19, 2026Total Debt (MRQ)
110.25KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0009xvs Biotechnology peers
Current Ratio (MRQ)
80.21xvs Biotechnology peers
Book Value per Share (MRQ)
10.15USDUpdated Jul 19, 2026Total Assets
94.00MUSDvs all stocks (USD)
Total Current Assets
93.98MUSDFY2025 · Dec 31, 2025Total Liabilities
7.49MUSDFY2025 · Dec 31, 2025Total Non-current Assets
19.50KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.06MUSDFY2025 · Dec 31, 2025Total Current Liabilities
6.43MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
3.50MUSDFY2025 · Dec 31, 2025Other Short-term Investments
89.51MUSDFY2025 · Dec 31, 2025Accounts Payable
1.57MUSDFY2025 · Dec 31, 2025Other Current Liabilities
-17.00USDFY2025 · Dec 31, 2025Common Stock (Book)
73.33KUSDFY2025 · Dec 31, 2025Retained Earnings
-698.27MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
86.51MUSDvs all stocks (USD)
52-Week Low
0.5500USDUpdated Jul 19, 202652-Week High
8.00USDUpdated Jul 19, 202652-Week Change
753.39%vs all stocks
50-Day MA
6.68USDUpdated Jul 19, 2026200-Day MA
5.06USDUpdated Jul 19, 2026Avg 10-Day Volume
1.72MSharesUpdated Jul 19, 2026Avg 30-Day Volume
2.26MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.09USDUpdated Jul 19, 2026Other Income / Expense
319.05KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 80.21×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 80.21Industry median: 5.64Industry P95: 23.02Peers compared: 261
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Price-to-book is 0.52×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 0.52Industry median: 2.97Industry P5: 1.03Peers compared: 261
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.55
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Morepen Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nanjing Well Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
NeuroPace Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Sailun Biotech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kingchem Liaoning Life Science Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Altimmune, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Orchid Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pulike Biological Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Wohua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Assure Tech Hangzhou Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule